See more : ARYZTA AG (0MFY.L) Income Statement Analysis – Financial Results
Complete financial analysis of Nexalin Technology, Inc. (NXL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nexalin Technology, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Ubiqconn Technology, Inc. (6928.TW) Income Statement Analysis – Financial Results
- Cypherpunk Holdings Inc. (CYFRF) Income Statement Analysis – Financial Results
- Revolve Group, Inc. (RVLV) Income Statement Analysis – Financial Results
- Golden Shield Resources Inc. (GSRI.CN) Income Statement Analysis – Financial Results
- The Liberty SiriusXM Group (LSXMB) Income Statement Analysis – Financial Results
Nexalin Technology, Inc. (NXL)
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 110.75K | 1.32M | 144.07K | 242.91K | 207.38K |
| Cost of Revenue | 25.69K | 363.21K | 21.44K | 29.04K | 218.21K |
| Gross Profit | 85.06K | 958.15K | 122.62K | 213.88K | -10.83K |
| Gross Profit Ratio | 76.80% | 72.51% | 85.12% | 88.05% | -5.22% |
| Research & Development | 1.92M | 511.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 5.78M | 2.79M | 6.14M | 3.47M | 78.13K |
| Selling & Marketing | 0.00 | 886.41K | 35.49K | 10.71K | 1.38M |
| SG&A | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Other Expenses | 0.00 | 171.68K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Cost & Expenses | 5.81M | 3.15M | 6.16M | 3.50M | 1.67M |
| Interest Income | 0.00 | 59.38K | 82.32K | 78.68K | 80.99K |
| Interest Expense | 38.84K | 59.38K | 82.32K | 78.68K | 80.99K |
| Depreciation & Amortization | 4.25K | 5.72K | 537.00 | 429.00 | 535.00 |
| EBITDA | -5.69M | -1.83M | -6.00M | -3.32M | -1.47M |
| EBITDA Ratio | -5,139.63% | -125.69% | -4,177.33% | -1,341.21% | -706.72% |
| Operating Income | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Operating Income Ratio | -5,143.48% | -138.72% | -4,177.70% | -1,341.38% | -706.98% |
| Total Other Income/Expenses | 1.05M | 135.22K | -59.40K | -145.08K | -3.56M |
| Income Before Tax | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Income Before Tax Ratio | -4,197.56% | -128.49% | -4,218.93% | -1,401.11% | -2,421.22% |
| Income Tax Expense | 0.00 | 228.00K | 82.32K | 78.68K | 5.00 |
| Net Income | -4.65M | -1.93M | -6.16M | -3.48M | -5.02M |
| Net Income Ratio | -4,197.56% | -145.75% | -4,276.07% | -1,433.50% | -2,421.22% |
| EPS | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| EPS Diluted | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
| Weighted Avg Shares Out (Dil) | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Report Highlights Nexalin's Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment Report Highlights Nexalin's Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET.
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has...
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Nexalin Technology, Inc. (Nasdaq:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this...
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this...
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI) HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Nexalin...
New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer's Treatment Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer's Treatment
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial...
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions
Source: https://incomestatements.info
Category: Stock Reports